IDH2 is altered in 10.54% of acute myeloid leukemia patients with IDH2 Codon 172 Missense present in 2.39% of all acute myeloid leukemia patients [4].

IDH2 Codon 172 Missense is an inclusion criterion in 6 clinical trials for acute myeloid leukemia, of which 6 are open and 0 are closed. Of the trials that contain IDH2 Codon 172 Missense and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [5].

IDH2 is altered in 4.88% of myelodysplastic syndromes patients with IDH2 Codon 172 Missense present in 0.73% of all myelodysplastic syndromes patients [4].

IDH2 Codon 172 Missense is an inclusion criterion in 5 clinical trials for myelodysplastic syndromes, of which 5 are open and 0 are closed. Of the trials that contain IDH2 Codon 172 Missense and myelodysplastic syndromes as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].

IDH2 is altered in 5.61% of chronic myelomonocytic leukemia patients with IDH2 Codon 172 Missense present in 0.51% of all chronic myelomonocytic leukemia patients [4].

IDH2 Codon 172 Missense is an inclusion criterion in 3 clinical trials for chronic myelomonocytic leukemia, of which 3 are open and 0 are closed. Of the trials that contain IDH2 Codon 172 Missense and chronic myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [5].

IDH2 is altered in 1.49% of myeloproliferative neoplasm patients with IDH2 Codon 172 Missense present in 0.1% of all myeloproliferative neoplasm patients [4].

IDH2 Codon 172 Missense is an inclusion criterion in 3 clinical trials for myeloproliferative neoplasm, of which 3 are open and 0 are closed. Of the trials that contain IDH2 Codon 172 Missense and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

IDH2 is altered in 9.88% of WHO grade II glioma patients with IDH2 Codon 172 Missense present in 8.95% of all WHO grade II glioma patients [4].

IDH2 Codon 172 Missense is an inclusion criterion in 1 clinical trial for WHO grade II glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Codon 172 Missense and WHO grade II glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

IDH2 is altered in 1.57% of anaplastic astrocytoma patients with IDH2 Codon 172 Missense present in 1.12% of all anaplastic astrocytoma patients [4].

IDH2 Codon 172 Missense is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Codon 172 Missense and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 is altered in 2.17% of diffuse astrocytoma patients with IDH2 Codon 172 Missense present in 1.09% of all diffuse astrocytoma patients [4].

IDH2 Codon 172 Missense is an inclusion criterion in 1 clinical trial for diffuse astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Codon 172 Missense and diffuse astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IDH2 is altered in 1.92% of malignant glioma patients with IDH2 Codon 172 Missense present in 1.06% of all malignant glioma patients [4].

IDH2 Codon 172 Missense is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 Codon 172 Missense and malignant glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].